Skip to main content
Erschienen in: International Urology and Nephrology 10/2017

19.06.2017 | Nephrology - Original Paper

Smoking as a risk factor for diabetic nephropathy: a meta-analysis

verfasst von: Sensen Su, Wanning Wang, Tao Sun, Fuzhe Ma, Yue Wang, Jia Li, Zhonggao Xu

Erschienen in: International Urology and Nephrology | Ausgabe 10/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Previous studies have investigated the connection between diabetic nephropathy and smoking, and reported widely varying rates. This study aimed to systematically analyze the impact of smoking on diabetic nephropathy.

Methods

We searched the PubMed and EMBASE electronic databases to identify relevant English-language studies published up to March 2016. Eligible studies were selected using inclusion and exclusion criteria. Data for each study were extracted independently by two authors. The homogeneity of the effect size across the studies was tested. Odds ratio (OR) was calculated by using the random-effect model. Sensitivity analysis was performed to reduce heterogeneity, and publication biases were examined.

Results

A total of 21 eligible studies were selected and pooled analyzed. No significant differences in demographic characteristics were found between patients with diabetic nephropathy and those with non-diabetic nephropathy. Significant heterogeneity across studies was found except those of diabetes mellitus controls. The aggregate OR of smoking in the patients with diabetic nephropathy in comparison with those with non-diabetic nephropathy was 1.70 (95% confidence interval 1.48–1.95). No evidence of publication bias was found.

Conclusion

Our findings indicate that smoking is a significant risk factor for diabetic nephropathy in diabetic patients.
Literatur
2.
Zurück zum Zitat Sun Y-M, Su Y, Li J et al (2013) Recent advances in understanding the biochemical and molecular mechanism of diabetic nephropathy. Biochem Biophys Res Commun 433(4):359–361CrossRefPubMed Sun Y-M, Su Y, Li J et al (2013) Recent advances in understanding the biochemical and molecular mechanism of diabetic nephropathy. Biochem Biophys Res Commun 433(4):359–361CrossRefPubMed
3.
Zurück zum Zitat Clair C, Cohen MJ, Eichler F et al (2015) The effect of cigarette smoking on diabetic peripheral neuropathy: a systematic review and meta-analysis. J Gen Intern Med 30(8):1193–1203CrossRefPubMedPubMedCentral Clair C, Cohen MJ, Eichler F et al (2015) The effect of cigarette smoking on diabetic peripheral neuropathy: a systematic review and meta-analysis. J Gen Intern Med 30(8):1193–1203CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Phisitkul K, Hegazy K, Chuahirun T et al (2008) Continued smoking exacerbates but cessation ameliorates progression of early type 2 diabetic nephropathy. Am J Med Sci 335(4):284–291CrossRefPubMed Phisitkul K, Hegazy K, Chuahirun T et al (2008) Continued smoking exacerbates but cessation ameliorates progression of early type 2 diabetic nephropathy. Am J Med Sci 335(4):284–291CrossRefPubMed
6.
Zurück zum Zitat Obert DM, Hua P, Pilkerton ME et al (2011) Environmental tobacco smoke furthers progression of diabetic nephropathy. Am J Med Sci 341(2):126–130CrossRefPubMedPubMedCentral Obert DM, Hua P, Pilkerton ME et al (2011) Environmental tobacco smoke furthers progression of diabetic nephropathy. Am J Med Sci 341(2):126–130CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Hua P, Feng W, Ji S et al (2010) Nicotine worsens the severity of nephropathy in diabetic mice: implications for the progression of kidney disease in smokers. Am J Physiol-Renal Physiol 299(4):F732–F739CrossRefPubMedPubMedCentral Hua P, Feng W, Ji S et al (2010) Nicotine worsens the severity of nephropathy in diabetic mice: implications for the progression of kidney disease in smokers. Am J Physiol-Renal Physiol 299(4):F732–F739CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Tarnow L, Groop P-H, Hadjadj S et al (2008) European rational approach for the genetics of diabetic complications—EURAGEDIC: patient populations and strategy. Nephrol Dial Transplant 23(1):161–168. doi:10.1093/ndt/gfm501 CrossRefPubMed Tarnow L, Groop P-H, Hadjadj S et al (2008) European rational approach for the genetics of diabetic complications—EURAGEDIC: patient populations and strategy. Nephrol Dial Transplant 23(1):161–168. doi:10.​1093/​ndt/​gfm501 CrossRefPubMed
9.
Zurück zum Zitat Li H, Feng S-J, Zhang G-Z et al (2014) Correlation of lower concentrations of hydrogen sulfide with atherosclerosis in chronic hemodialysis patients with diabetic nephropathy. Blood Purif 38(3–4):188–194. doi:10.1159/000368883 CrossRefPubMed Li H, Feng S-J, Zhang G-Z et al (2014) Correlation of lower concentrations of hydrogen sulfide with atherosclerosis in chronic hemodialysis patients with diabetic nephropathy. Blood Purif 38(3–4):188–194. doi:10.​1159/​000368883 CrossRefPubMed
10.
Zurück zum Zitat Afkarian M, Sachs MC, Kestenbaum B et al (2013) Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol: ASN. 2012070718 Afkarian M, Sachs MC, Kestenbaum B et al (2013) Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol: ASN. 2012070718
11.
Zurück zum Zitat Hovind P, Rossing P, Tarnow L et al (2003) Smoking and progression of diabetic nephropathy in type 1 diabetes. Diabetes Care 26(3):911–916CrossRefPubMed Hovind P, Rossing P, Tarnow L et al (2003) Smoking and progression of diabetic nephropathy in type 1 diabetes. Diabetes Care 26(3):911–916CrossRefPubMed
12.
Zurück zum Zitat Lau J, Ioannidis JP, Schmid CH (1997) Quantitative synthesis in systematic reviews. Ann Intern Med 127(9):820–826CrossRefPubMed Lau J, Ioannidis JP, Schmid CH (1997) Quantitative synthesis in systematic reviews. Ann Intern Med 127(9):820–826CrossRefPubMed
16.
Zurück zum Zitat Ahmed MA, Kishore G, Khader HA et al (2013) Risk factors and management of diabetic nephropathy. Saudi J Kidney Dis Transpl 24(24):1242–1247CrossRefPubMed Ahmed MA, Kishore G, Khader HA et al (2013) Risk factors and management of diabetic nephropathy. Saudi J Kidney Dis Transpl 24(24):1242–1247CrossRefPubMed
17.
Zurück zum Zitat Baum L, Ng MC, So WY, Lam VK et al (2005) Effect of hepatic lipase -514C- > T polymorphism and its interactions with apolipoprotein C3–482C- > T and apolipoprotein E exon 4 polymorphisms on the risk of nephropathy in Chinese type 2 diabetic patients. Diabetes Care 28(7):1704–1709CrossRefPubMed Baum L, Ng MC, So WY, Lam VK et al (2005) Effect of hepatic lipase -514C- > T polymorphism and its interactions with apolipoprotein C3–482C- > T and apolipoprotein E exon 4 polymorphisms on the risk of nephropathy in Chinese type 2 diabetic patients. Diabetes Care 28(7):1704–1709CrossRefPubMed
18.
Zurück zum Zitat Furukawa S, Yamamoto S, Todo Y et al (2014) Association between subclinical hypothyroidism and diabetic nephropathy in patients with type 2 diabetes mellitus. Endocr J 61(10):1011–1018CrossRefPubMed Furukawa S, Yamamoto S, Todo Y et al (2014) Association between subclinical hypothyroidism and diabetic nephropathy in patients with type 2 diabetes mellitus. Endocr J 61(10):1011–1018CrossRefPubMed
20.
Zurück zum Zitat Khalid AR, Youssef AM, Subhani SN et al (2014) Diabetic nephropathy and its risk factors in a society with a type 2 diabetes epidemic: a Saudi National Diabetes Registry-based study. PLoS ONE 9(2):e88956CrossRef Khalid AR, Youssef AM, Subhani SN et al (2014) Diabetic nephropathy and its risk factors in a society with a type 2 diabetes epidemic: a Saudi National Diabetes Registry-based study. PLoS ONE 9(2):e88956CrossRef
21.
Zurück zum Zitat Korpinen E, Groop PH, Rautio A et al (1999) N-acetyltransferase-2 polymorphism, smoking and type 1 diabetic nephropathy. Pharmacogenet Genomics 9(5):627–633CrossRef Korpinen E, Groop PH, Rautio A et al (1999) N-acetyltransferase-2 polymorphism, smoking and type 1 diabetic nephropathy. Pharmacogenet Genomics 9(5):627–633CrossRef
22.
Zurück zum Zitat Lajer M, Jorsal A, Tarnow L et al (2010) Plasma growth differentiation factor-15 independently predicts all-cause and cardiovascular mortality as well as deterioration of kidney function in type 1 diabetic patients with nephropathy. Diabetes Care 33(7):1567–1572. doi:10.2337/dc09-2174 CrossRefPubMedPubMedCentral Lajer M, Jorsal A, Tarnow L et al (2010) Plasma growth differentiation factor-15 independently predicts all-cause and cardiovascular mortality as well as deterioration of kidney function in type 1 diabetic patients with nephropathy. Diabetes Care 33(7):1567–1572. doi:10.​2337/​dc09-2174 CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Liu L, Zheng T, Wang F et al (2010) Pro12Ala polymorphism in the PPARG gene contributes to the development of diabetic nephropathy in Chinese type 2 diabetic patients. Diabetes Care 33(1):144–149. doi:10.2337/dc09-1258 CrossRefPubMed Liu L, Zheng T, Wang F et al (2010) Pro12Ala polymorphism in the PPARG gene contributes to the development of diabetic nephropathy in Chinese type 2 diabetic patients. Diabetes Care 33(1):144–149. doi:10.​2337/​dc09-1258 CrossRefPubMed
24.
Zurück zum Zitat Mollsten A, Marklund SL, Wessman M et al (2007) A functional polymorphism in the manganese superoxide dismutase gene and diabetic nephropathy. Diabetes 56(1):265–269. doi:10.2337/db06-0698 CrossRefPubMed Mollsten A, Marklund SL, Wessman M et al (2007) A functional polymorphism in the manganese superoxide dismutase gene and diabetic nephropathy. Diabetes 56(1):265–269. doi:10.​2337/​db06-0698 CrossRefPubMed
25.
Zurück zum Zitat Ngarmukos C, Bunnag P, Kosachunhanun N et al (2006) Thailand diabetes registry project: prevalence, characteristics and treatment of patients with diabetic nephropathy. J Med Assoc Thai 89(Suppl 1):S37–S42PubMed Ngarmukos C, Bunnag P, Kosachunhanun N et al (2006) Thailand diabetes registry project: prevalence, characteristics and treatment of patients with diabetic nephropathy. J Med Assoc Thai 89(Suppl 1):S37–S42PubMed
26.
Zurück zum Zitat Ozaki R, Cheung KKT, Wu E et al (2011) A new tool to detect kidney disease in Chinese type 2 diabetes patients: comparison of EZSCAN with standard screening methods. Diabetes Technol Ther 13(9):937–943. doi:10.1089/dia.2011.0023 CrossRefPubMed Ozaki R, Cheung KKT, Wu E et al (2011) A new tool to detect kidney disease in Chinese type 2 diabetes patients: comparison of EZSCAN with standard screening methods. Diabetes Technol Ther 13(9):937–943. doi:10.​1089/​dia.​2011.​0023 CrossRefPubMed
27.
Zurück zum Zitat Rossing P, Hougaard P, Parving HH (2002) Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study. BMJ 25(5):859–864 Rossing P, Hougaard P, Parving HH (2002) Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study. BMJ 25(5):859–864
28.
30.
Zurück zum Zitat Theilade S, Lajer M, Jorsal A et al (2012) Evaluation of placental growth factor and soluble Fms-like tyrosine kinase 1 as predictors of all-cause and cardiovascular mortality in patients with type 1 diabetes with and without diabetic nephropathy. Diabet Med 29(3):337–344. doi:10.1111/j.1464-5491.2011.03482.x CrossRefPubMed Theilade S, Lajer M, Jorsal A et al (2012) Evaluation of placental growth factor and soluble Fms-like tyrosine kinase 1 as predictors of all-cause and cardiovascular mortality in patients with type 1 diabetes with and without diabetic nephropathy. Diabet Med 29(3):337–344. doi:10.​1111/​j.​1464-5491.​2011.​03482.​x CrossRefPubMed
32.
Zurück zum Zitat Zheng S, Powell DW, Zheng F et al (2016) Diabetic Nephropathy: Proteinuria, Inflammation, and Fibrosis. J Diabetes Res 2016 Zheng S, Powell DW, Zheng F et al (2016) Diabetic Nephropathy: Proteinuria, Inflammation, and Fibrosis. J Diabetes Res 2016
33.
Zurück zum Zitat Kanwar YS, Wada J, Sun L et al (2008) Diabetic nephropathy: mechanisms of renal disease progression. Exp Biol Med 233(1):4–11CrossRef Kanwar YS, Wada J, Sun L et al (2008) Diabetic nephropathy: mechanisms of renal disease progression. Exp Biol Med 233(1):4–11CrossRef
34.
Zurück zum Zitat Ritz E, Ogata H, Orth S (2008) Smoking: a factor promoting onset and progression of diabetic nephropathy Ritz E, Ogata H, Orth S (2008) Smoking: a factor promoting onset and progression of diabetic nephropathy
35.
Zurück zum Zitat Voulgari C, Katsilambros N, Tentolouris N (2011) Smoking cessation predicts amelioration of microalbuminuria in newly diagnosed type 2 diabetes mellitus: a 1-year prospective study. Metabolism 60(10):1456–1464CrossRefPubMed Voulgari C, Katsilambros N, Tentolouris N (2011) Smoking cessation predicts amelioration of microalbuminuria in newly diagnosed type 2 diabetes mellitus: a 1-year prospective study. Metabolism 60(10):1456–1464CrossRefPubMed
36.
Zurück zum Zitat Scott LJ, Warram JH, Hanna LS et al (2001) A nonlinear effect of hyperglycemia and current cigarette smoking are major determinants of the onset of microalbuminuria in type 1 diabetes. Diabetes 50(12):2842–2849CrossRefPubMed Scott LJ, Warram JH, Hanna LS et al (2001) A nonlinear effect of hyperglycemia and current cigarette smoking are major determinants of the onset of microalbuminuria in type 1 diabetes. Diabetes 50(12):2842–2849CrossRefPubMed
37.
Zurück zum Zitat Prince CT, Secrest AM, Mackey RH et al (2010) Cardiovascular autonomic neuropathy, HDL cholesterol, and smoking correlate with arterial stiffness markers determined 18 years later in type 1 diabetes. Diabetes Care 33(3):652–657CrossRefPubMed Prince CT, Secrest AM, Mackey RH et al (2010) Cardiovascular autonomic neuropathy, HDL cholesterol, and smoking correlate with arterial stiffness markers determined 18 years later in type 1 diabetes. Diabetes Care 33(3):652–657CrossRefPubMed
Metadaten
Titel
Smoking as a risk factor for diabetic nephropathy: a meta-analysis
verfasst von
Sensen Su
Wanning Wang
Tao Sun
Fuzhe Ma
Yue Wang
Jia Li
Zhonggao Xu
Publikationsdatum
19.06.2017
Verlag
Springer Netherlands
Erschienen in
International Urology and Nephrology / Ausgabe 10/2017
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-017-1638-3

Weitere Artikel der Ausgabe 10/2017

International Urology and Nephrology 10/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.